Short Interest in Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF) Grows By 26.7%

Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 615,400 shares, an increase of 26.7% from the December 15th total of 485,600 shares. Based on an average trading volume of 100 shares, the days-to-cover ratio is presently 6,154.0 days.

Recordati Industria Chimica e Farmaceutica Stock Performance

OTCMKTS:RCDTF remained flat at $55.54 during trading hours on Friday. The company has a market capitalization of $11.46 billion, a P/E ratio of 27.77 and a beta of 0.30. Recordati Industria Chimica e Farmaceutica has a 52 week low of $52.25 and a 52 week high of $52.25. The firm has a fifty day moving average price of $53.19 and a 200 day moving average price of $52.47.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on RCDTF shares. Royal Bank of Canada upgraded shares of Recordati Industria Chimica e Farmaceutica to a “hold” rating in a research report on Monday, October 7th. Barclays raised shares of Recordati Industria Chimica e Farmaceutica to a “strong sell” rating in a research note on Tuesday, October 22nd.

Recordati Industria Chimica e Farmaceutica Company Profile

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.